SAN DIEGO COUNTY - News from Jan. 18, 1992
Amylin’s Offering a Success: On its first day of public trading, Amylin Pharmaceuticals shares closed at $20.75 over the counter, up sharply from Friday’s initial offering price of $14. The company sold 4 million shares, bringing its total outstanding to 16.8 million.
Founded in 1987, Amylin is a San Diego-based biotechnology company developing products for the treatment of diabetes and associated health problems, including certain types of obesity. The company’s technology focuses on amylin, a hormone the company says may play a major role in the regulation of human glucose metabolism.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
